摘要
目的研究并应用一种改良的抑制素（Ｉｎｈｉｂｉｎ，ＩＮＨ）放射免疫测定（ＲＩＡ）。方法对卵巢颗粒细胞瘤、卵泡膜细胞瘤及卵巢上皮性肿瘤等多种卵巢肿瘤进行监测。结果１．卵巢颗粒细胞瘤、卵泡膜细胞瘤和卵巢粘液性囊腺癌及恶性畸胎瘤患者血浆ＩＮＨ浓度均值高于其他肿瘤患者，差异非常显著，Ｐ＜０．０１。２．卵巢颗粒细胞瘤、卵泡膜细胞瘤和粘液性囊腺癌及内膜样癌患者血浆ＩＮＨ值术前异常升高，术后一周降至正常范围，并可动态监测病情变化。结论１．改良的ＩＮＨＲＩＡ方法方便、省时、定量、敏感性高。２．ＩＮＨ可作为卵巢肿瘤的良好监测指标，与ＣＡ┐１２５联合应用，将有助于卵巢癌的早期诊断。
Objective:A modified radioimmunoassay (RIA) for plasma inhibin (INH) was developed for monitoring ovarian tumors.Methods:The plasma INH in 39 cases of fertile and 16 cases of postmenopausal women, and 33 various ovarian tumors patients were tested for. Results:1.Plasma INH in follicular,periovulation and midluteal phases of fertile women were 9.48±7.10 pg/ml,19.04±9.73 pg/ml and 131.13±110.81 pg/ml respectively.Plasma INH was negatively correlated with serum FSH (rs=-0483,P<001),and was <36 pg/ml in normal postmenopausal women. 2. Plasma INH in ovarian granulosa cell tumor(GCT), thecoma(TMA), mucinous cystadenocarcinoma(MCA) and malignant teratoma cases were significantly higher than in other ovarian tumors,P<001. 3. Plasma INH were elevated in GCT, TMA,MCA and endometrioid carcinoma cases befroe operation, but fell to normal range within one week after operation. Successive INH RIA could monitor the therapeutic efficacy.Conclusion:1. Modified INH RIA is convenient, time-saving,quantitative and highly sensitive(<1 pg/ml). 2.Plasma INH content changes regularly during menstrual cycle,and can inhibit the production and secretion of FSH. 3. INH would be a valuable marker for ovarian tumors. INH RIA in combine with plasma CA125 test would be helpful to early diagnosis, treatment and prognosis of ovarian cancer.
出处
《肿瘤》
CAS
CSCD
北大核心
1998年第5期322-325,共4页
Tumor
